Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus ELOCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus ELOCON.
ALA-SCALP vs ELOCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Elocon (mometasone furoate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to increased synthesis of lipocortins that inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene formation. It also suppresses cytokine production and inflammatory cell migration.
Topical application of a 5% solution to the scalp twice daily.
Apply a thin film to affected skin area once daily. Use no more than 45 g per week.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life approximately 5-7 hours after topical application. Systemic half-life is short, limiting systemic accumulation with topical use.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily hepatic metabolism; metabolites excreted renally and in feces. Approximately 60% of a topical dose is excreted in urine as metabolites, 30% in feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid